Osteogenix

Osteogenix, Inc. was a therapeutic products company established in 2005 and headquartered in Palo Alto, California. The firm focused on developing and commercializing an osteo-pharmacologic platform with the goal of creating products that accelerate bone repair and growth. This technology centered on a proprietary bone anabolic agent designed to stimulate new bone formation.

The company's primary market was in orthopedics, specifically targeting bone growth therapies. Its business model was centered on research and development, aiming to advance its proprietary agent through preclinical and clinical trials. In March 2007, Osteogenix entered into a significant development agreement with the spine business of Medtronic, a major medical technology company. Under this pact, Osteogenix was tasked with completing preclinical work and moving its bone anabolic agent into clinical trials, providing Medtronic with a new pipeline for bone growth therapies.

Financially, Osteogenix secured venture capital to support its research efforts. The company raised a total of $2.05 million, including a notable early-stage venture round of $1.45 million on February 21, 2007. Shalon Ventures was one of the institutional investors backing the company. The strategic collaboration with Medtronic culminated in the acquisition of Osteogenix by Medtronic on December 1, 2010, integrating its promising bone growth technology into the portfolio of a global industry leader.

Keywords: bone repair, bone growth, osteo-pharmacologic, therapeutic products, Medtronic acquisition, orthopedic therapies, bone anabolic agent, preclinical trials, Shalon Ventures, Palo Alto startup, medical technology, bone regeneration, orthopedic biologics, venture capital, therapeutic devices, clinical development